Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015

Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 31

Yuta Aizawa, Kanako Watanabe, Tomohiro Oishi, Harunobu Hirano, Isao Hasegawa, and Akihiko SaitohComments to Author 
Author affiliations: Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan (Y. Aizawa, T. Oishi, A. Saitoh); Niigata University Graduate School of Health Sciences, Niigata (K. Watanabe); Saiseikai Niigata Daini Hospital, Niigata (H. Hirano, I. Hasegawa); University of California San Diego School of Medicine, San Diego, California, USA (A. Saitoh)

Main Article

Table 3

Summary of rates of HPeV type 3 seropositivity and neutralization assay methods used in previous studies and in study in Niigata, Japan*

Study location Seropositivity rate, % (no. samples) Maternal age range, y Cutoff Cells used for viral culture Virus strain
Aichi, Japan (8) 74 (92) 15–39 1:8 Vero A308/1999
Finland (15) 13 (72) 21–40 1:16 Vero FI0688
Netherlands (15) 10 (77) 16–60 1:16 Vero FI0688
This study 61 (175)† 16–44 1:32 LLC-MK2 A308/1999

*HPeV, human parechovirus.
†Maternal antibody seropositivity rate.

Main Article

  1. RacanielloR. Picornaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 6th ed. Vol. 1. Philadelphia: Lippincott, Williams and Wilkins; 2013. p. 610–64.
  2. Wildenbeest  JG, Harvala  H, Pajkrt  D, Wolthers  KC. The need for treatment against human parechoviruses: how, why and when? Expert Rev Anti Infect Ther. 2010;8:141729. DOIPubMedGoogle Scholar
  3. Watanabe  K, Oie  M, Higuchi  M, Nishikawa  M, Fujii  M. Isolation and characterization of novel human parechovirus from clinical samples. Emerg Infect Dis. 2007;13:88995. DOIPubMedGoogle Scholar
  4. Japan National Institute of Infectious Diseases. Monthly reports of parechovirus isolation/detection, January 2005–May 2015 [cited 2015 Apr 13].
  5. Chhabra  P, Payne  DC, Szilagyi  PG, Edwards  KM, Staat  MA, Shirley  SH, Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008–2009. J Infect Dis. 2013;208:790800. DOIPubMedGoogle Scholar
  6. Pajkrt  D, Benschop  KS, Westerhuis  B, Molenkamp  R, Spanjerberg  L, Wolthers  KC. Clinical characteristics of human parechoviruses 4–6 infections in young children. Pediatr Infect Dis J. 2009;28:100810. DOIPubMedGoogle Scholar
  7. Benschop  KS, Schinkel  J, Minnaar  RP, Pajkrt  D, Spanjerberg  L, Kraakman  HC, Human parechovirus infections in Dutch children and the association between serotype and disease severity. Clin Infect Dis. 2006;42:20410. DOIPubMedGoogle Scholar
  8. Ito  M, Yamashita  T, Tsuzuki  H, Takeda  N, Sakae  K. Isolation and identification of a novel human parechovirus. J Gen Virol. 2004;85:3918. DOIPubMedGoogle Scholar
  9. Harvala  H, Robertson  I, Chieochansin  T, McWilliam Leitch  EC, Templeton  K, Simmonds  P. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis. 2009;199:175360. DOIPubMedGoogle Scholar
  10. Wolthers  KC, Benschop  KS, Schinkel  J, Molenkamp  R, Bergevoet  RM, Spijkerman  IJ, Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis. 2008;47:35863. DOIPubMedGoogle Scholar
  11. Selvarangan  R, Nzabi  M, Selvaraju  SB, Ketter  P, Carpenter  C, Harrison  CJ. Human parechovirus 3 causing sepsis-like illness in children from midwestern United States. Pediatr Infect Dis J. 2011;30:23842. DOIPubMedGoogle Scholar
  12. Verboon-Maciolek  MA, Groenendaal  F, Hahn  CD, Hellmann  J, van Loon  AM, Boivin  G, Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol. 2008;64:26673. DOIPubMedGoogle Scholar
  13. Sedmak  G, Nix  WA, Jentzen  J, Haupt  TE, Davis  JP, Bhattacharyya  S, Infant deaths associated with human parechovirus infection in Wisconsin. Clin Infect Dis. 2010;50:35761. DOIPubMedGoogle Scholar
  14. Esposito  S, Rahamat-Langendoen  J, Ascolese  B, Senatore  L, Castellazzi  L, Niesters  HG. Pediatric parechovirus infections. J Clin Virol. 2014;60:849. DOIPubMedGoogle Scholar
  15. Westerhuis  B, Kolehmainen  P, Benschop  K, Nurminen  N, Koen  G, Koskiniemi  M, Human parechovirus seroprevalence in Finland and the Netherlands. J Clin Virol. 2013;58:2115.DOIPubMedGoogle Scholar
  16. Pallansch  MA, Weldon  WC, Penaranda  S, Klatte  M, Harrison  C, Pate  B, Human parechovirus 3 seroprevalence amongst mothers of young infants in the United States. In: Abstracts of the 29th Clinical Virology Symposium; April 28–May 1, 2013; Daytona Beach, Florida, USA. Session S77. Pan American Society for Clinical Virology; 2013 [cited 2015 Apr 10].
  17. Stoll, Barbara  J. Infections of the neonatal infant. In: Kliegman RM, Stanton BF, St. Geme JW, Schor NF, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Saunders Elsevier; 2011. p. 629–48.
  18. Mohamed  N, Elfaitouri  A, Fohlman  J, Friman  G, Blomberg  J. A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for detection of enteroviral RNA. J Clin Virol. 2004;30:1506. DOIPubMedGoogle Scholar
  19. Corey  L, Huang  ML, Selke  S, Wald  A. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol. 2005;76:3505. DOIPubMedGoogle Scholar
  20. Nix  WA, Maher  K, Johansson  ES, Niklasson  B, Lindberg  AM, Pallansch  MA, Detection of all known parechoviruses by real-time PCR. J Clin Microbiol. 2008;46:251924. DOIPubMedGoogle Scholar
  21. Hyypiä  T, Horsnell  C, Maaronen  M, Khan  M, Kalkkinen  N, Auvinen  P, A distinct picornavirus group identified by sequence analysis. Proc Natl Acad Sci U S A. 1992;89:884751. DOIPubMedGoogle Scholar
  22. Condit, Richard  C. Principles of virology. In: Knipe DM, Howley PM, editors. Fields virology. 6th ed. Vol 1. Philadelphia: Lippincott, Williams and Wilkins; 2013. p. 21–51.
  23. Ito  M, Yamashita  T, Tsuzuki  H, Kabashima  Y, Hasegawa  A, Nagaya  S, Detection of human parechoviruses from clinical stool samples in Aichi, Japan. J Clin Microbiol. 2010;48:26838. DOIPubMedGoogle Scholar
  24. Foo  DG, Alonso  S, Chow  VT, Poh  CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299306. DOIPubMedGoogle Scholar
  25. Westerhuis  BM, Koen  G, Wildenbeest  JG, Pajkrt  D, de Jong  MD, Benschop  KS, Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development. J Gen Virol. 2012;93:236370. DOIPubMedGoogle Scholar
  26. Schuffenecker  I, Javouhey  E, Gillet  Y, Kugener  B, Billaud  G, Floret  D, Human parechovirus infections, Lyon, France, 2008–10: evidence for severe cases. J Clin Virol. 2012;54:33741. DOIPubMedGoogle Scholar
  27. Tauriainen  S, Martiskainen  M, Oikarinen  S, Lonnrot  M, Viskari  H, Ilonen  J, Human parechovirus 1 infections in young children–no association with type 1 diabetes. J Med Virol. 2007;79:45762. DOIPubMedGoogle Scholar
  28. Kolehmainen  P, Oikarinen  S, Koskiniemi  M, Simell  O, Ilonen  J, Knip  M, Human parechoviruses are frequently detected in stool of healthy Finnish children. J Clin Virol. 2012;54:15661. DOIPubMedGoogle Scholar
  29. Yang  C, Deng  C, Wan  J, Zhu  L, Leng  Q. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J. 2011;8:306. DOIPubMedGoogle Scholar
  30. Wildenbeest  JG, Wolthers  KC, Straver  B, Pajkrt  D. Successful IVIG treatment of human parechovirus-associated dilated cardiomyopathy in an infant. Pediatrics. 2013;132:e2437. DOIPubMedGoogle Scholar
  31. Abzug  MJ, Keyserling  HL, Lee  ML, Levin  MJ, Rotbart  HA. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis. 1995;20:12016. DOIPubMedGoogle Scholar

Main Article

1Presented in part at IDWeek, October 8–12, 2014, Philadelphia, Pennsylvania, USA.

Page created: October 16, 2015
Page updated: October 16, 2015
Page reviewed: October 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.